NeuroPace Inc
NeuroPace Inc is listed today as NeuroPace, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2020 | $69 M | No. 4 | $50 to $250 million | equity | SEC | |
| Sep 2016 | $72 M | No. 3 | $50 to $250 million | equity | SEC | |
| Jul 2013 | $18 M | No. 2 | $10 to $50 million | equity | SEC | |
| Aug 2011 | $49 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
NeuroPace Inc chose not to state its revenue in its newest notice of a funding round (Aug 2020).
SEC Form D · Aug 2020
The industry group it chose in its notices: Other Health Care.
SEC Form D · Aug 2020
That is all the official record says: NeuroPace Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of NeuroPace Inc are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Accelmed Partners II L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Frank M. Fischer | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| KCK LTD. | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| OrbiMed Capital GP VI LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 26 investors.
Largest shareholders today
Institutions holding NeuroPace, Inc. shares, as of Sep 30, 2026.
- First Light Asset Management, LLC$55 M11.56%
- Polar Capital Holdings Plc$45 M9.57%
- Soleus Capital Management, L.P.$44 M9.34%
- Morgan Stanley$35 M7.46%
- BlackRock, Inc.$34 M7.16%
- Driehaus Capital Management LLC$20 M4.15%
- Vanguard Capital Management LLC$17 M3.58%
- Orbimed Advisors LLC$15 M3.06%
- Deutsche Bank AG\$13 M2.72%
- Armistice Capital, LLC$11 M2.32%
- Geode Capital Management, LLC$9 M1.92%
- State Street Corp$8 M1.64%
- Silvercrest Asset Management Group LLC$4 M0.91%
- Qube Research & Technologies Ltd$4 M0.88%
- D. E. Shaw & Co., Inc.$4 M0.76%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Frank Fischer | Executive officer | Aug 2020 |
| Mike Favet | Executive officer | Aug 2020 |
| Rebecca Kuhn | Executive officer | Aug 2020 |
| Debra Smolley | Executive officer | Jul 2013 |
| Isabella Abati | Executive officer | Jul 2013 |
| Martha Morrell | Executive officer | Jul 2013 |
| Evan Norton | Director | Aug 2020 |
| Frank Fischer | Director | Aug 2020 |
| Greg Garfield | Director | Aug 2020 |
| Joseph Lacob | Director | Aug 2020 |
| Mike Favet | Director | Aug 2020 |
| Nael Kassar | Director | Aug 2020 |
| Renee Ryan | Director | Aug 2020 |
| Rishi Gupta | Director | Aug 2020 |
| Vince Burgess | Director | Aug 2020 |
| Jonathan Silverstein | Director | Aug 2017 |
| Ray Larkin | Director | Aug 2017 |
| Benjamin Pless | Director | Jul 2013 |
| Chuck Newhall | Director | Jul 2013 |
| David Fischell | Director | Jul 2013 |
| James Blair | Director | Jul 2013 |
| Brad Vale | Director | Aug 2011 |
About
NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation..
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.